| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2024 | LIFESENSORS INC | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R44AG066271 | Novel Approaches for Tau PROTAC Drug Discovery | 000 | 3 | NIH | 6/5/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $1,545,064 ) |
| | 2024 | 2024 | LIFESENSORS INC | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43GM156150 | Molecular glue degraders for LRRK2 | 000 | 1 | NIH | 8/13/2024 | $299,978 |
| | 2024 | 2024 | LIFESENSORS INC | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R44AG066271 | Novel Approaches for Tau PROTAC Drug Discovery | 000 | 3 | NIH | 5/17/2024 | $1,245,086 |
| | 2024 | 2022 | LIFESENSORS INC | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R44GM134737 | Rational design of bifunctional protein degrader drugs | 000 | 3 | NIH | 9/24/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,254,532 ) |
| | 2023 | 2023 | LIFESENSORS INC | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R44AG066271 | Novel Approaches for Tau PROTAC Drug Discovery | 000 | 2 | NIH | 7/14/2023 | $1,254,536 |
| | 2023 | 2020 | LIFESENSORS, INC. | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43AI155218 | Development of Non-conventional PROTACs | 001 | 1 | NIH | 9/7/2023 | $0 |
| | 2023 | 2020 | LIFESENSORS INC | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43AI155218 | Development of Non-conventional PROTACs | 000 | 1 | NIH | 8/25/2023 | $0 |
| | 2023 | 2020 | LIFESENSORS INC | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R44AG057231 | Ubiquitin Proteasome System and Molecular Signatures of Alzheimer's Disease | 000 | 3 | NIH | 12/9/2022 | -$4 |
| | 2023 | 2020 | LIFESENSORS INC | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43AG066271 | Novel Approaches for PROTAC Drug Discovery | 000 | 1 | NIH | 7/10/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $733,586 ) |
| | 2022 | 2022 | LIFESENSORS INC | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R44GM134737 | Rational design of bifunctional protein degrader drugs | 000 | 3 | NIH | 7/18/2022 | $733,586 |
| | 2022 | 2019 | LIFESENSORS INC | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R44AG054313 | Linkage-specific ubiquitylation patterns as highly sensitive markers for neurodegenerative disease | 000 | 3 | NIH | 1/26/2022 | $0 |
| | 2022 | 2019 | LIFESENSORS INC | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43AG062061 | Determining the signatures of pan-ubiquitylation in the immune proteome as highly sensitive and effective markers for neurodegenerative disease | 000 | 1 | NIH | 11/15/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,004,186 ) |
| | 2021 | 2021 | LIFESENSORS, INC. | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R44GM134737 | Rational design of bifunctional protein degrader drugs | 000 | 2 | NIH | 3/26/2021 | $1,004,186 |
| | 2021 | 2019 | LIFESENSORS, INC. | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43GM134737 | Rational design of bifunctional protein degrader drugs | 000 | 1 | NIH | 3/25/2021 | $0 |
| | 2021 | 2019 | LIFESENSORS, INC. | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43GM134737 | Rational design of bifunctional protein degrader drugs | 001 | 1 | NIH | 8/29/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,482,393 ) |
| | 2020 | 2020 | LIFESENSORS, INC. | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R44AG057231 | Ubiquitin Proteasome System and Molecular Signatures of Alzheimer's Disease | 000 | 3 | NIH | 8/10/2020 | $785,292 |
| | 2020 | 2020 | LIFESENSORS, INC. | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43AI155218 | Development of Non-conventional PROTACs | 000 | 1 | NIH | 7/20/2020 | $300,000 |
| | 2020 | 2020 | LIFESENSORS, INC. | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43AG066271 | Novel Approaches for PROTAC Drug Discovery | 000 | 1 | NIH | 9/11/2020 | $397,101 |
| | 2020 | 2019 | LIFESENSORS, INC. | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43GM134737 | Rational design of bifunctional protein degrader drugs | 000 | 1 | NIH | 11/18/2019 | $0 |
| | 2020 | 2017 | LIFESENSORS, INC. | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43AG057231 | Development of chain selective polyubiquitin markers as early detectors of Parkinson?s and Alzheimer?s Disease | 000 | 1 | NIH | 2/9/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $2,316,268 ) |
| | 2019 | 2019 | LIFESENSORS, INC. | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R44AG057231 | Ubiquitin Proteasome System and Molecular Signatures of Alzheimer's Disease | 000 | 2 | NIH | 8/26/2019 | $1,012,084 |
| | 2019 | 2019 | LIFESENSORS, INC. | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R44AG054313 | Linkage-specific ubiquitylation patterns as highly sensitive markers for neurodegenerative disease | 000 | 3 | NIH | 5/20/2019 | $779,745 |
| | 2019 | 2019 | LIFESENSORS, INC. | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43GM134737 | Rational design of bifunctional protein degrader drugs | 000 | 1 | NIH | 6/27/2019 | $299,611 |
| | 2019 | 2019 | LIFESENSORS, INC. | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43AG062061 | Determining the signatures of pan-ubiquitylation in the immune proteome as highly sensitive and effective markers for neurodegenerative disease | 000 | 1 | NIH | 5/29/2019 | $224,828 |
| | 2019 | 2016 | LIFESENSORS, INC. | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43AG054313 | Linkage-specific ubiquitylation patterns as highly sensitive markers for neurodegenerative disease | 000 | 1 | NIH | 10/25/2018 | $0 |
| | 2019 | 2016 | LIFESENSORS, INC. | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43AG055250 | Novel assays for assessing protein-protein interactions in Alzheimer's disease | 000 | 1 | NIH | 10/25/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $718,511 ) |
| | 2018 | 2018 | LIFESENSORS, INC. | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R44AG054313 | Linkage-specific ubiquitylation patterns as highly sensitive markers for neurodegenerative disease | 000 | 2 | NIH | 9/21/2018 | $718,511 |
| | 2018 | 2015 | LIFESENSORS, INC. | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R44CA165561 | Development of linkage-specific ubiquitin binding elements | 001 | 4 | NIH | 3/20/2018 | -$871 |
| | 2018 | 2014 | LIFESENSORS, INC. | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R44CA165561 | Development of linkage-specific ubiquitin binding elements | 000 | 3 | NIH | 1/29/2018 | $871 |
|
| Issue Date FY: 2017 ( Subtotal = $180,585 ) |
| | 2017 | 2017 | LIFESENSORS, INC. | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43AG057231 | Development of chain selective polyubiquitin markers as early detectors of Parkinson?s and Alzheimer?s Disease | 000 | 1 | NIH | 8/29/2017 | $190,258 |
| | 2017 | 2014 | LIFESENSORS, INC. | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43GM110883 | Deciphering the poly-ubiquitin code with isopeptide selective antibodies | 000 | 1 | NIH | 11/3/2016 | -$8,802 |
| | 2017 | 2014 | LIFESENSORS, INC. | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43GM109585 | Selective inhibitors of deubiquitylases | 000 | 1 | NIH | 11/4/2016 | $0 |
| | 2017 | 2013 | LIFESENSORS, INC. | 271 GREAT VALLEY PKWY | MALVERN | PA | 19355-1308 | CHESTER | USA | R43CA165561 | Identification and characterization of linkage-specific ubiquitin binding element | 000 | 2 | NIH | 5/8/2017 | -$871 |
|
| Issue Date FY: 2016 ( Subtotal = $449,336 ) |
| | 2016 | 2016 | LIFESENSORS INC | 271 GREAT VALLEY PARKWAY | MALVERN | PA | 19355-1326 | CHESTER | USA | R43AG054313 | Linkage-specific ubiquitylation patterns as highly sensitive markers for neurodegenerative disease | 000 | 1 | NIH | 8/29/2016 | $224,662 |
| | 2016 | 2016 | LIFESENSORS INC | 271 GREAT VALLEY PARKWAY | MALVERN | PA | 19355-1326 | CHESTER | USA | R43AG055250 | Novel assays for assessing protein-protein interactions in Alzheimer's disease | 000 | 1 | NIH | 9/15/2016 | $224,674 |
|
| Issue Date FY: 2015 ( Subtotal = $739,313 ) |
| | 2015 | 2015 | LIFESENSORS INC | 271 GREAT VALLEY PARKWAY | MALVERN | PA | 19355-1326 | CHESTER | USA | R44CA165561 | Development of linkage-specific ubiquitin binding elements | 000 | 4 | NIH | 8/4/2015 | $739,313 |
| | 2015 | 2014 | LIFESENSORS INC | 271 GREAT VALLEY PARKWAY | MALVERN | PA | 19355 | CHESTER | USA | R43GM110883 | Deciphering the poly-ubiquitin code with isopeptide selective antibodies | 000 | 1 | NIH | 6/30/2015 | $0 |
|
| Issue Date FY: 2014 ( Subtotal = $1,183,348 ) (Continued on the next page) |
| | 2014 | 2014 | LIFESENSORS INC | 271 GREAT VALLEY PARKWAY | MALVERN | PA | 19355-1326 | CHESTER | USA | R43GM110883 | Deciphering the poly-ubiquitin code with isopeptide selective antibodies | 000 | 1 | NIH | 6/5/2014 | $223,710 |
|
